The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored
Dermaflutisone Dosage
Generic name: Dermaflutisone PROPIONATE 55ug
Dosage form: inhalation powder, metered
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
General
Dermaflutisone should be administered only by the orally inhaled route. Advise the patient to rinse his/her mouth with water without swallowing after each dose.
Dosing
Dermaflutisone should be administered as 1 inhalation twice daily (approximately 12 hours apart) by the orally inhaled route. Dermaflutisone should be used at approximately the same time every day. Do not use Dermaflutisone more than 2 times every 24 hours.
The starting dosage for Dermaflutisone is based upon patients’ asthma severity. The usual recommended starting dose for patients not on inhaled corticosteroids is 55 mcg twice daily. For other patients, the starting dose should be based on previous asthma drug therapy and disease severity. For patients switching to Dermaflutisone from another inhaled corticosteroid product, select the low (55 mcg), medium (113 mcg) or high (232 mcg) dose strength of Dermaflutisone based on the strength of the previous inhaled corticosteroid product and disease severity. For patients who do not respond to Dermaflutisone 55 mcg after 2 weeks of therapy, increasing the dose may provide additional asthma control.
If a dosage regimen of Dermaflutisone fails to provide adequate control of asthma, the therapeutic regimen should be re-evaluated and additional therapeutic options (e.g., replacing the current strength of Dermaflutisone with a higher strength, or adding additional controller therapies) should be considered.
The highest recommended dose is 232 mcg twice daily. If symptoms arise between doses, an inhaled short-acting beta2-agonist should be used for immediate relief.
The maximum benefit may not be achieved for up to 2 weeks or longer after starting treatment. Individual patients will experience a variable time to onset and degree of symptom relief. After asthma stability has been achieved, it is desirable to titrate to the lowest effective dosage to reduce the possibility of side effects. The safety and efficacy of Dermaflutisone when administered in excess of recommended dosages have not been established.
Dermaflutisone does not require priming. Do not use Dermaflutisone with a spacer or volume holding chamber.
Cleaning:
•
Keep the inhaler in a cool dry place. Never wash or put any part of the inhaler in water.
•
Routine maintenance is not required. If the mouthpiece needs cleaning, gently wipe the mouthpiece with a dry cloth or tissue as needed.
Dose Counter: The Dermaflutisone inhaler has a dose counter. When the patient receives the inhaler, the number 60 will be displayed. The dose counter will count down each time the mouthpiece is opened and closed. The dose counter window displays the number of actuations (inhalations) left in the inhaler in units of two (e.g., 60, 58, 56, etc.). When the dose counter reaches 20, the color of the numbers will change to red to remind the patient to contact their pharmacist for a refill of medication or consult their physician for a prescription refill. When the dose counter reaches 0, the background will change to solid red and the color of the numbers will change to black.
Tell your doctor about all other medicines you use, especially:
conivaptan (Vaprisol);
imatinib (Gleevec);
isoniazid (for treating tuberculosis);
nefazodone;
an antibiotic such as clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), or telithromycin (Ketek);
antifungal medication such as itraconazole (Sporanox), ketoconazole (Nizoral), miconazole (Oravig), or voriconazole (Vfend);
heart or blood pressure medication such as nicardipine (Cardene) or quinidine (Quin-G);
HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), or saquinavir (Invirase).
This list is not complete and other drugs may interact with Dermaflutisone nasal. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Dermaflutisone interactions
Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Dermaflutisone, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored
Under normal circumstances, low plasma concentrations of Dermaflutisone propionate are achieved after inhaled dosing, due to extensive first-pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 (CYP450 3A4) in the gut and liver. Hence, clinically significant drug interactions mediated by Dermaflutisone propionate are unlikely.
A drug interaction study in healthy subjects has shown that ritonavir (a highly potent CYP450 3A4 inhibitor) can greatly increase Dermaflutisone propionate plasma concentrations, resulting in markedly reduced serum cortisol concentrations. During post-marketing use, there have been reports of clinically significant drug interactions in patients receiving Dermaflutisone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. Therefore, concomitant use of Dermaflutisone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.
Caution should be exercised when other potent CYP450 3A4 inhibitors are co-administered with Dermaflutisone propionate. In a drug interaction study, co-administration of orally inhaled Dermaflutisone propionate (1,000 mcg) and ketoconazole (200 mg once daily) resulted in increased plasma Dermaflutisone propionate exposure and reduced plasma cortisol area under the concentration-time curve (AUC), but had no effect on urinary excretion of cortisol. In another multiple-dose drug interaction study, co-administration of orally inhaled Dermaflutisone propionate (500 mcg twice daily) and erythromycin (333 mg 3 times daily) did not affect Dermaflutisone propionate pharmacokinetics.
sponsored
Reviews
The results of a survey conducted on ndrugs.com for Dermaflutisone are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Dermaflutisone. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported frequency of use
No survey data has been collected yet
Consumer reported doses
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
